|
Online CME Activity
50-Year-Old Woman with Uncontrolled T2DM: Current Complaints of Fatigue and Blurry Vision, Paresthesias
|
50-Year-Old Woman with Uncontrolled T2DM: Current Complaints of Fatigue and Blurry Vision, Paresthesias
2.00 AMA PRA Category 1 Credits™, 2.00 AANP, 2.00 ANCC
Learning Objective
1. Reduce the risk of diabetes-related complications through treatment intensification.
2. Implement treatment strategies to achieve glycemic goals based on patient A1C levels.
Accreditation
This educational program is conceived and credited in accordance with ACCME's Essential Areas and Policies, including the 2004 Updated Standards for Commercial Support. Pri-Med faculty hail from a variety of institutions and participate in content development, along with pmiCME's Advisory Boards and its expert review partners, the University of Wisconsin School of Medicine and Public Health and Tufts Health Care Institute. All final decisions about program content are the responsibility of pmiCME.
| Credits |
Type |
Accreditation Statement |
Designation Statement |
| 2.00 |
AMA PRA Category 1 Credits™ |
pmiCME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. |
pmiCME designates this educational activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. |
| 2.00 |
AANP |
pmiCME is approved as a provider of nurse practitioner continuing education programs by the American Academy of Nurse Practitioners. AANP Provider number 040308. |
This program has been approved for 2 contact hours of continuing education, which includes 1 hours of pharmacology. |
| 2.00 |
ANCC |
pmiCME is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. |
This activity for 2 contact hours is provided by pmiCME. |
Faculty and Editorial Board
Written By:
Jeff Unger, MD, FAAFP, Catalina Research Institute, Chino, California
Reviewed By:
Tufts University School of Medicine
Edited By:
Christopher Drury, pmiCME, Boston, MA
Financial Disclosure Statement(s)
Jeff Unger, MD, is a consultant to Amylin, Novo Nordisk Inc, and Roche. He is a speakers’ bureau member for Amylin Pharmaceuticals, Inc.; Eli Lilly and Co.; and Novo Nordisk Inc.; and he receives grants for contracted research from Novo Nordisk Inc., GlaxoSmithKline, sanofi-aventis, Roche, Forest Pharmaceuticals, AstraZeneca Pharmaceuticals LP, Takeda Pharmaceuticals North America, Daiichi Sankyo Inc., Ortho-McNeil, Arena, Wyeth, Cephalon, Proctor & Gamble, Allergan, and Abbott Laboratories. Dr Unger also receives royalty fees from Lippincott Williams & Wilkins for the Diabetes Management in Primary Care textbook.
The content collaborators at Global Directions in Medicine, Inc. have no financial relationships to disclose.
Mr Drury has no financial relationships to disclose.
Education Partner:
Global Directions in Medicine, Inc.
Pri-Med Disclaimer
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed, nor do they necessarily reflect, those of their affiliated institutions, pmiCME, pmiCME Advisory Boards and Consultants, or M|C Communications, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.
|
|
|
